Edgewise Therapeutics, Inc. Stock Price, News & Analysis

Edgewise Therapeutics (NASDAQ:EWTX) will present key findings on sevasemten, their oral treatment for Becker and Duchenne muscular dystrophies, at the 30th International Annual Congress of the World Muscle Society in Vienna, Austria (October 7-11, 2025).

The company will host a symposium on October 8, 2025, featuring presentations from key opinion leaders discussing natural history insights and clinical progress. Three scientific posters will be presented on October 10, highlighting results from the CANYON trial in Becker muscular dystrophy, trajectory data compared to natural history, and LYNX Phase 2 trial results in DMD that will inform Phase 3 design.

Edgewise Therapeutics (Nasdaq: EWTX), a biopharmaceutical company focused on muscle diseases, has granted inducement stock options to 2 new non-executive employees. The options allow the purchase of 16,500 shares at an exercise price of $14.35 per share, matching the closing price on the grant date of August 29, 2025.

The options, granted under the company's 2024 Inducement Equity Incentive Plan, will vest over four years, with 25% vesting after one year and the remaining vesting monthly at a rate of 1/48th, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 2025 financial results and clinical progress. The company announced positive top-line data from multiple trials of sevasemten in muscular dystrophy patients. Key highlights include 99% enrollment in the MESA open-label extension trial for Becker muscular dystrophy, showing sustained disease stabilization over 18 months.

The company completed enrollment of 175 adults in the GRAND CANYON pivotal trial, with topline data expected in Q4 2026. For Duchenne muscular dystrophy, encouraging results were reported from the LYNX and FOX Phase 2 trials. Additionally, Edgewise is advancing its CIRRUS-HCM Phase 2 trial of EDG-7500 for Hypertrophic Cardiomyopathy.

Financially, Edgewise maintains a strong position with $594.0 million in cash and equivalents. Q2 2025 R&D expenses were $33.6 million, down from $36.8 million in Q1, with a net loss of $36.1 million ($0.34 per share).

Edgewise Therapeutics (NASDAQ: EWTX), a biopharmaceutical company focused on muscle diseases, has granted equity-based inducement awards to 3 new non-executive employees. The awards include 84,250 stock options with an exercise price of $14.26 per share and 5,000 restricted stock units (RSUs).

The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments starting July 31, 2025. These awards were granted under the company's 2024 Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Edgewise Therapeutics (NASDAQ:EWTX) reported positive results for sevasemten in treating Becker and Duchenne muscular dystrophies. The MESA open-label trial showed sustained disease stabilization for up to three years in Becker patients, with a 0.8-point improvement in NSAA scores over 18 months.

Following a successful FDA Type C meeting, the company received clarity on the registration path for sevasemten as the first-ever Becker therapy. The GRAND CANYON pivotal trial is progressing toward topline data in Q4 2026. Additionally, Phase 2 trials (LYNX and FOX) in Duchenne patients identified 10 mg as the optimal dose for Phase 3, with plans to initiate the pivotal study in 2026.

Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, announced its upcoming presentation at the Annual Goldman Sachs Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 3:20 pm ET. The event will be available through a live webcast on the company's Events & Presentations page, with replay access available for a limited time after the conference. Attendees are advised to connect several minutes before the presentation starts to ensure proper connection.

Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation in the RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for Tuesday, May 20, 2025, at 9:00 am ET. The event will feature a live webcast accessible through the company's Events & Presentations page, with replay availability for a limited time after the conference. Attendees are advised to connect several minutes before the start time to ensure proper connection.

Edgewise Therapeutics (NASDAQ: EWTX) reported Q1 2025 financial results and business updates. The company announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy. They strengthened their financial position through a $200M public offering, resulting in pro-forma cash balance exceeding $624M. Key developments include: completed enrollment in GRAND CANYON trial for Becker muscular dystrophy with 175 adults; positive data from CANYON trial; and advancing CIRRUS-HCM trial showing promising results. Q1 2025 financials showed R&D expenses of $36.8M and net loss of $40.8M ($0.43 per share). The company expects to report data from Phase 2 LYNX and FOX trials in Duchenne muscular dystrophy in Q2 2025 and Part D of CIRRUS-HCM trial in H2 2025.

Edgewise Therapeutics (NASDAQ: EWTX) has announced the pricing of an underwritten offering of 9,935,419 shares of common stock at $20.13 per share, expecting to raise approximately $200 million in gross proceeds. The offering, set to close on April 3, 2025, features participation from notable investors including Braidwell LP, Cormorant Asset Management, and OrbiMed.

The net proceeds will support the potential U.S. commercial launch of sevasemten for Becker muscular dystrophy patients, advance Phase 3 trials for sevasemten in Duchenne muscular dystrophy, and fund Phase 3 trials of EDG-7500 in patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The offering is being managed by Leerink Partners, Piper Sandler, Guggenheim Securities, and Truist Securities as joint book-running managers.